Avastin Receives Broad Label Extension In Europe For The Treatment Of Patients With Metastatic Colorectal Cancer

Avastin Receives Broad Label Extension In Europe For The Treatment Of Patients With Metastatic Colorectal Cancer
Roche announced that the European Commission (EC) has given its approval for the significantly wider use of its anti-angiogenic agent Avastin (bevacizumab) in patients suffering from metastatic colorectal cancer. This new broader label will now allow Avastin to be used in combination with any chemotherapy, including Roche's oral chemotherapy Xeloda (capecitabine)*, for 1st and later treatment lines in patients with metastatic colorectal cancer.

Arius Completes Pre-IND Meeting With FDA For Lead CD44 Cancer Stem Cell Program
ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, announced it has completed its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate.

Safe Removal Of Gliomas To Preserve Language Requires Less Extensive Brain Exposure Than Previously Thought
A more limited approach to craniotomy---the procedure through which a patient's skull is opened up to expose the brain---than has traditionally been used by neurosurgeons can maximize resection and minimize lasting side effects when tumours within or near language pathways are removed, according to the results of a prospective study published in the New England Journal of Medicine.

Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, Is More Efficacious, Less Toxic Than Gossypol In Animal Models
Coronado Biosciences Inc. announced the publication of data demonstrating that the Bcl-2 inhibitor, Apogossypol, effectively killed a variety of cancer cells in vitro while demonstrating less toxicity than Gossypol in vivo in mice. Published online in Blood (Jan. 17, DOI 10.1182/blood-2007-09-113647) by the Burnham Institute's president and CEO, John Reed, M.D., Ph.D.

Race Against Time To Save Tasmanian Devils
A delegation of Tasmanian government officials traveled halfway around the world to visit Cold Spring Harbor Laboratory (CSHL), to lend their support and extend their gratitude for research aimed at understanding a unique transmissible and rapidly spreading cancer that threatens the very existence of Tasmanian devils.